JP2022513375A5 - - Google Patents
Info
- Publication number
- JP2022513375A5 JP2022513375A5 JP2021547056A JP2021547056A JP2022513375A5 JP 2022513375 A5 JP2022513375 A5 JP 2022513375A5 JP 2021547056 A JP2021547056 A JP 2021547056A JP 2021547056 A JP2021547056 A JP 2021547056A JP 2022513375 A5 JP2022513375 A5 JP 2022513375A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- ppm1d
- nampt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748911P | 2018-10-22 | 2018-10-22 | |
| US62/748,911 | 2018-10-22 | ||
| PCT/US2019/057386 WO2020086547A1 (en) | 2018-10-22 | 2019-10-22 | IDENTIFICATION OF PPM1D MUTATIONS AS A NOVEL BIOMARKER FOR NAMPTi SENSITIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513375A JP2022513375A (ja) | 2022-02-07 |
| JP2022513375A5 true JP2022513375A5 (cg-RX-API-DMAC7.html) | 2022-10-27 |
Family
ID=70330533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547056A Withdrawn JP2022513375A (ja) | 2018-10-22 | 2019-10-22 | ＮＡＭＰＴｉ感受性のバイオマーカーとしてのＰＰＭ１Ｄ変異の同定法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210369681A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3870166A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022513375A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114096243A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117152A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020086547A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119015414A (zh) * | 2023-05-23 | 2024-11-26 | 中国科学院动物研究所 | Wip1或Coro1a的医药用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101384264B (zh) * | 2004-09-22 | 2012-03-14 | 辉瑞大药厂 | 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物 |
| US20080318892A1 (en) * | 2006-04-28 | 2008-12-25 | John Geoffrey Pickering | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
| SG11201408770RA (en) * | 2012-06-27 | 2015-01-29 | Alzheimer S Inst Of America Inc | Compounds and therapeutic uses thereof |
| GB201220924D0 (en) * | 2012-11-21 | 2013-01-02 | Cancer Res Inst Royal | Materials and methods for determining susceptibility or predisposition to cancer |
| CN106458934B (zh) * | 2014-04-18 | 2019-08-16 | 米伦纽姆医药公司 | 喹喔啉化合物及其用途 |
| US20210180138A1 (en) * | 2017-11-06 | 2021-06-17 | Mor Research Applications Ltd. | Methods for prognosis and treatment of solid tumors |
-
2019
- 2019-10-22 CN CN201980084245.8A patent/CN114096243A/zh active Pending
- 2019-10-22 US US17/285,849 patent/US20210369681A1/en not_active Abandoned
- 2019-10-22 JP JP2021547056A patent/JP2022513375A/ja not_active Withdrawn
- 2019-10-22 EP EP19876311.2A patent/EP3870166A4/en not_active Withdrawn
- 2019-10-22 CA CA3117152A patent/CA3117152A1/en active Pending
- 2019-10-22 WO PCT/US2019/057386 patent/WO2020086547A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bernstock et al. | Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications | |
| TWI794171B (zh) | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 | |
| JP7427655B2 (ja) | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 | |
| JP6761852B2 (ja) | がん治療 | |
| US11084829B2 (en) | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| KR20160006668A (ko) | 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물 | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2022033783A (ja) | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 | |
| JP2019011376A (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
| Oishi et al. | Halofuginone treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model | |
| JP2024527109A5 (cg-RX-API-DMAC7.html) | ||
| Kerbel | Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs | |
| JP2017519006A5 (cg-RX-API-DMAC7.html) | ||
| Wei et al. | Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets | |
| JP2018516936A5 (cg-RX-API-DMAC7.html) | ||
| Oh et al. | Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study: CR Oh et al. | |
| JP2025063134A (ja) | 化学療法抵抗性がんの組合せ処置 | |
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| NO20066080L (no) | Behandling med irinotecan (CPT-11) og en AGFR-inhibitor | |
| Xie et al. | RETRACTED: Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy | |
| WO2021102420A1 (en) | Interferon signaling as a cancer biomarker | |
| Wolin | Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors | |
| Wu et al. | Nicotinamide adenine dinucleotide alleviates neuroinflammation in rats with traumatic brain injury |